fashion -WSS

fashion

author：fashion 2025-09-30 06:09:09 - browse：71297

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

knowledge

hotspot

WSS

Despite FDA concern, risk that CAR

Will the market for weight loss drugs really reach $100 billion?

FDA investigates CAR

How to address the problem of discarded donor organs

Pfizer highlights cancer drugs it thinks could reignite investor interest

J&J to emphasize cancer drugs, stop much of its vaccine research

leisure time

fashion

explore

Activists slam private health insurers over coverage restrictions

How to address the problem of discarded donor organs

Hepatitis C has a cure — but many Americans still lack access to it

Fetal surgery at risk from Dobbs and new abortion restrictions

The high cost of giving birth even with insurance

Organ aging and disease risk measured by new blood test

Guidelines to prevent youth baseball injuries need more muscle

BIO selects John Crowley as new CEO

The high cost of giving birth even with insurance

As biotech industry slumps, bioscience job market is upside down

focus

Will the market for weight loss drugs really reach $100 billion?

Clinical trials giant ICON acquires HumanFirst

Takeda, Janssen join wearable maker to measure scratching

Why getting cancer drugs just got harder for rural patients

House looks to weaken Medicare negotiation

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Wikipedia

knowledge

hotspot

focus